[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356190-105":59,"doc-detail-356190-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-landscape-and-emerging-trends-of-pd-1pd-l1-research-in-prostate-cancer-a-data-driven-atlas-from-multidatabase-integration","Current landscape and emerging trends of PD-1/PD-L1 research in prostate cancer - A data-driven atlas from multidatabase integration","","Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) blockade has changed treatment in multiple malignancies, yet its role in prostate cancer remains unclear. Combination therapy, tumor-microenvironment modulation, and biomarker-guided patient selection drive the need to define research trends. Web of Science and Scopus data were analyzed with CiteSpace, VOSviewer, R, and Python, with PubMed screened clinical-trial reports. 2,641 publications were included, showing rising activity after 2014 and a 2022 peak, with heterogeneous clinical-trial evidence suggesting biomarker-defined benefit requiring prospective validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-landscape-and-emerging-trends-of-pd-1pd-l1-research-in-prostate-cancer-a-data-driven-atlas-from-multidatabase-integration/356190/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-landscape-and-emerging-trends-of-pd-1pd-l1-research-in-prostate-cancer-a-data-driven-atlas-from-multidatabase-integration/356190.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this data-driven atlas on PD-1/PD-L1 research in prostate cancer?","Question",{"text":112,"@type":113},"To map knowledge structure, research hotspots, thematic evolution, and clinical-trial evidence for PD-1/PD-L1 in prostate cancer using a multidatabase approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and analytical tools were used to study publication trends?",{"text":117,"@type":113},"Publications were retrieved from Web of Science Core Collection and Scopus, and trends and knowledge flow were analyzed using CiteSpace, VOSviewer, R, and Python.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study report about research activity over time and the 2022 peak?",{"text":121,"@type":113},"Annual publications increased after 2014 and reached a peak in 2022, indicating growing momentum before that high point.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356190,1790528208,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","HUMAN VACCINES & IMMUNOTHERAPEUTICS 2026, VOL. 22, NO. 1, 2727809 [https://doi.org/10.1080/21645515.2026.2727809](https://doi.org/10.1080/21645515.2026.2727809)  \nRESEARCH ARTICLE     \nCurrent landscape and emerging trends of PD-1/PD-L1 research in prostate cancer: A data-driven atlas from multidatabase integration  \nBingxin Zhoua*, Xinyu Jub*, Jun Wangc*, Xingyu Zhud, Xudong Yua, Yichao Wua, Yuewan Fua, Peilin Wua, Lianying Songa, and Yaosheng Zhanga  \naDongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing, China; bDepartment of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical University, Bengbu, Anhui, China; cAnhui Provincial Acupuncture Hospital, Anhui University of Chinese Medicine, Hefei, Anhui, China; dDepartment of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, China  \nABSTRACT  \nAlthough programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) blockade has transformed treatment in several malignancies, its role in prostate cancer remains uncertain. Interest in combination therapy, tumor-microenvironment modulation, and biomarker-guided selection highlights the need to clarify research trends. To characterize the knowledge structure, hotspots, thematic evolution, and clinical-trial evidence on PD-1/PD-L1 in prostate cancer. Publications were retrieved from the Web of Science Core Collection and Scopus. CiteSpace, VOSviewer, R, and Python were used to analyze publication trends, collaboration networks, thematic evolution, and knowledge flow. Clinical-trial reports identified in PubMed were screened and summarized. A total of 2,641 publications were included, comprising 1,421 original articles and 1,220 reviews, involving 17,180 authors and 4,658 keywords. Annual publications increased after 2014 and reached a peak in 2022. Among the candidate models, the logistic model performed best (AIC = 116.4), with the fitted trajectory suggesting a possible slowing. The United States and China were the leading contributors, whereas Canada, Germany, and the United Kingdom showed higher proportions of multinational collaboration. Research increasingly emphasized mechanism-driven and precision-oriented strategies, while exploratory and pan-cancer studies remain part of its knowledge base. The 13 included clinical trials covered diverse combination, but evidence was heterogeneous and no standardized treatment paradigm has yet been established. This multidatabase delineates the knowledge structure, evolution, and emerging directions of PD-1/PD-L1 research in prostate cancer. Current evidence indicates limited activity in unselected populations, whereas potential benefit may be concentrated in biomarker-defined subgroups and selected combinations requiring prospective validation.  \nARTICLE HISTORY  \nReceived 17 May 2026 Revised 27 July 2026 Accepted 30 August 2026  \nKEYWORDS  \nProstate cancer; programmed cell death protein-1; programmed death-ligand 1; immunotherapy; tumor microenvironment; immune checkpoint inhibitors; multidatabase analysis  \nIntroduction  \nProstate cancer (PCa) remains a prevalent malignancy among men worldwide.1 In 2020, an estimated 1,414,259 new cases were reported worldwide,2 and both its incidence and mortality have continued to increase.3,4 Localized disease is managed with radical prostatectomy (RP), radiotherapy, and androgen deprivation therapy (ADT) .5 Nevertheless, patients remain at risk of prostate-specific antigen (PSA) elevation, biochemical recurrence (BCR), and metastatic progression after primary treatment.6–8 Some patients ultimately develop castration-resistant prostate cancer (CRPC), which is associated with a poor prognosis.9  \nImmunotherapy has emerged as a potential therapeutic strategy for mCRPC.10, 11 The advent of sipuleucel-T marked an important milestone in the development of immunotherapy for advanced PCa. 12 Immune checkpoint pathways, particularly those mediated by cytotoxic T-lymp","cbCaidMrd0cMQKOE","https://ap.wps.com/l/cbCaidMrd0cMQKOE","pdf",17961961,25,"English","# Abstract\n# Introduction\n## Background on prostate cancer\n## Rationale for PD-1/PD-L1 research\n# Methods and data sources\n## Publication retrieval and analysis tools\n## Clinical-trial screening\n# Results\n## Publication volume and temporal trends\n## Collaboration patterns and countries\n## Modeling and trajectory insights\n## Emphasis on mechanisms and precision strategies\n## Clinical-trial evidence overview\n# Conclusion and implications","[{\"question\":\"What was the purpose of this data-driven atlas on PD-1/PD-L1 research in prostate cancer?\",\"answer\":\"To map knowledge structure, research hotspots, thematic evolution, and clinical-trial evidence for PD-1/PD-L1 in prostate cancer using a multidatabase approach.\"},{\"question\":\"Which databases and analytical tools were used to study publication trends?\",\"answer\":\"Publications were retrieved from Web of Science Core Collection and Scopus, and trends and knowledge flow were analyzed using CiteSpace, VOSviewer, R, and Python.\"},{\"question\":\"What did the study report about research activity over time and the 2022 peak?\",\"answer\":\"Annual publications increased after 2014 and reached a peak in 2022, indicating growing momentum before that high point.\"}]","Current landscape and emerging trends of PD-1/PD-L1 research in prostate cancer - A data-driven atlas from multidatabase integration | PDF",1790123954,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57b1b9a993052a1b4113932de72b8e91.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86571986c46123c6757449ec5c7a917b.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53c89f7c65f257cec85efd426a626786.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1fa3a0ef02382bc1f1dfa5f92259d3c.webp",980,1306]